Results 271 to 280 of about 438,171 (330)

Mechanical Cues Regulate Cargo Sorting and Export at the Golgi

Advanced Science, EarlyView.
A pathway is identified linking extracellular matrix stiffness to secretion via Src–FAK–AMPK–GBF1 signaling. Golgi‐localized GBF1 acts as a mechanotransducer whose phosphorylation controls post‐Golgi cargo sorting toward secretion or lysosomal degradation.
Greta Serafino, Stefania Forciniti, Edoardo Scarpa, Antonio Ranieri, Lucia Santorelli, Gabriella De Blasi, Sara Costantini, Eunjoo Jun Lee, Antonio Galeone, Alessia Calcagnì, Marinella Pirozzi, Loretta L. del Mercato, Rossella Venditti, Giovanni D'Angelo, Seetharaman Parashuraman, Tiziano Verri, Giuseppe Gigli, Elizabeth S. Sztul, Paolo Grumati, Loris Rizzello, Domenico Russo, Riccardo Rizzo   +21 more
wiley   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

METTL10‐Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression

Advanced Science, EarlyView.
METTL10‐mediated methylation of PIAS3 at K442 inhibits its SUMO E3 ligase activity toward MITF. This reduces MITF SUMOylation and subsequent RNF4‐mediated ubiquitination, leading to MITF protein accumulation and gastric cancer progression. Abstract Metabolic dysregulation plays a significant role in the development of gastric cancer (GC).
Jinshui Tan, Huiwen Zhou, Jingsong Ma, Chensong Zhang, Yuhua Tan, Baoding Zhang, Jiabao Zhao, Ao Cheng, Chengyu Yang, Meijuan Xu, Shengyi Zhou, Yubo Xiong, Zeyang Lin, Guangchao Pan, Wenjie Ye, Mengya Zhong, Yang Yang, Yifan Zhuang, Shao‐Wei Li, Xianming Deng, Xuehui Hong   +20 more
wiley   +1 more source

Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression

Advanced Science, EarlyView.
This study identifies SPTAN1‐kla as a novel oncogenic driver in HBV‐driven HCC, linking metabolic, epigenetic, and immune mechanisms. SPTAN1‐kla promotes HCC progression via NOTCH1/HES1 activation and immunosuppression. Findings highlight that targeting SPTAN1‐kla provides a framework for HCC treatment to improve clinical outcomes in HBV infected ...
Zengbin Wang, Dongjie Ye, Linqing Wu, Jiayu Liu, Banglun Pan, Zhu Zhang, Xiaoxia Zhang, Yuxin Yao, Nanhong Tang   +8 more
wiley   +1 more source

YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination

Advanced Science, EarlyView.
The SNARE protein YKT6 is upregulated in bladder cancer (BLCA), correlating with poor prognosis. YKT6 promotes tumor proliferation and metastasis by activating Wnt/β‐catenin signaling. It recruits Ubiquitin‐Specific Peptidase 7 (USP7) to deubiquitinate and stabilize β‐catenin, enhancing its nuclear accumulation and driving oncogenic gene expression ...
Sheng Tu, Wenzhi Du, Yongwen Luo, Jiageng Shi, Tianyun Liu, Meng Ji, Kangping Xiong, Siming Chen, Fenfang Zhou, Mingxing Li, Jingtian Yu, Gang Wang, Lingao Ju, Yi Zhang, Yu Xiao, Xinghuan Wang, Kaiyu Qian   +16 more
wiley   +1 more source

Tumor immunology.

The Western journal of medicine, 2010
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor Immunology

2007
Advances in tumor immunology are supporting the clinical implementation of several immunological approaches to cancer in the clinical setting. However, the alternate success of current immunotherapeutic regimens underscores the fact that the molecular mechanisms underlying immune-mediated tumor rejection are still poorly understood.
MOCELLIN, SIMONE, LISE M, NITTI, DONATO
openaire   +4 more sources

Tumor immunology

Current Opinion in Oncology, 1991
The underlying premise of tumor immunology is that the immune system is capable of recognizing cancer cells and that immune recognition can lead to rejection of tumors by the host. We focus on recent advances in tumor immunology in experimental systems, including the molecular identification of tumor antigens, studies of recognition of tumor cells by ...
C, Naftzger, A N, Houghton
openaire   +2 more sources

MODELING TUMOR IMMUNOLOGY

Mathematical Models and Methods in Applied Sciences, 2006
The aim of this paper is to discuss biological and computational models of tumor-immune system interactions. To this end we provid first a short introduction to the field of general immunology, then a more in-depth exposition of cancer immunology. Finally we discuss a first approach to vaccine that prevent tumor onset from a biological point of view ...
LOLLINI P. L, MOTTA, Santo, PAPPALARDO, FRANCESCO   +2 more
openaire   +4 more sources

Immunology of genitourinary tumors

Urology, 1973
Abstract A summary of basic tumor immunology is presented, including the evidence which supports the concept that urologic tumors are antigenic and that the host reacts against these tumors. Possible applications of urologic tumor immunology available to the clinician are discussed.
P, Guinan, N, Sadoughi, I M, Bush, T, John, F, Eghrari, R J, Ablin   +5 more
openaire   +2 more sources